A muti-modal feature fusion method based on deep learning for predicting immunotherapy response.

Journal: Journal of theoretical biology
Published Date:

Abstract

Immune checkpoint therapy (ICT) has greatly improved the survival of cancer patients in the past few years, but only a small number of patients respond to ICT. To predict ICT response, we developed a multi-modal feature fusion model based on deep learning (MFMDL). This model utilizes graph neural networks to map gene-gene relationships in gene networks to low dimensional vector spaces, and then fuses biological pathway features and immune cell infiltration features to make robust predictions of ICT. We used five datasets to validate the predictive performance of the MFMDL. These five datasets span multiple types of cancer, including melanoma, lung cancer, and gastric cancer. We found that the prediction performance of multi-modal feature fusion model based on deep learning is superior to other traditional ICT biomarkers, such as ICT targets or tumor microenvironment-associated markers. In addition, we also conducted ablation experiments to demonstrate the necessity of fusing different modal features, which can improve the prediction accuracy of the model.

Authors

  • Xiong Li
    School of Software, East China Jiaotong University, Nanchang, 330013, China.
  • Xuan Feng
    School of Software, East China Jiaotong University, Nanchang 330013, China.
  • Juan Zhou
    Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
  • Yuchao Luo
    School of Software, East China Jiaotong University, Nanchang 330013, China.
  • Xiao Chen
  • Jiapeng Zhao
    School of Software, East China Jiaotong University, Nanchang 330013, China.
  • HaoWen Chen
    College of Information Science and Engineering, Hunan University, Changsha, Hunan, 410082, China.
  • Guoming Xiong
    School of Software, East China Jiaotong University, Nanchang 330013, China.
  • Guoliang Luo
    School of Software, East China Jiaotong University, Nanchang 330013, China.